Choudhary Patel
Psychiatry · Long Beach, CANPI 1003843863
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,676 and has fallen 83.9% since, to $270 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$802
- Alkermes, Inc.$522
- Teva Pharmaceuticals USA, Inc.$438
- Neurocrine Biosciences, Inc.$424
- Otsuka America Pharmaceutical, Inc.$350
- Vanda Pharmaceuticals Inc.$323
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,15298%
- Education$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 36 | $802 |
| Alkermes, Inc. | 23 | $522 |
| Teva Pharmaceuticals USA, Inc. | 21 | $438 |
| Neurocrine Biosciences, Inc. | 19 | $424 |
| Otsuka America Pharmaceutical, Inc. | 17 | $350 |
| Vanda Pharmaceuticals Inc. | 14 | $323 |
| AbbVie(2 entities) | 14 | $292 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $276 |
| Ironshore Pharmaceuticals Inc. | 8 | $166 |
| Sunovion Pharmaceuticals Inc. | 13 | $161 |
| Lundbeck LLC | 5 | $119 |
| Corium, LLC | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $89 |
| Neuronetics, Inc. | 2 | $47 |
| Sage Therapeutics, LLC | 1 | $30 |
| Mirum Pharmaceuticals, Inc. | 1 | $23 |
| Tris Pharma Inc | 1 | $19 |
| Indivior Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$123
How this compares
$4,254 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $128,247 |
| Lurasidone Hcl | 32 | $4,165 |
| Aripiprazole | 50 | $3,962 |
| Olanzapine | 63 | $2,828 |
| Duloxetine Hcl | 70 | $2,728 |
| Trazodone Hcl | 185 | $2,592 |
| Ziprasidone Hcl | 26 | $2,509 |
| Quetiapine Fumarate | 70 | $2,222 |
| Fluphenazine Hcl | 33 | $1,478 |
| Buspirone Hcl | 132 | $1,286 |
| Divalproex Sodium | 18 | $1,080 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $613 |
| Mirtazapine | 30 | $602 |
| Sertraline Hcl | 34 | $564 |
| Bupropion XlBupropion Hcl | 15 | $458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $424 | $128,24715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Long Beach
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.